Literature DB >> 22624718

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.

Rosa Lapalombella1, Yuh-Ying Yeh1, Liwen Wang2, Asha Ramanunni1, Sarwish Rafiq3, Shruti Jha1, Justin Staubli3, David M Lucas4, Rajeswaran Mani5, Sarah E M Herman3, Amy J Johnson4, Arletta Lozanski1, Leslie Andritsos1, Jeffrey Jones1, Joseph M Flynn1, Brian Lannutti6, Peter Thompson7, Paul Algate8, Scott Stromatt8, David Jarjoura9, Xiaokui Mo9, Dasheng Wang10, Ching-Shih Chen4, Gerard Lozanski11, Nyla A Heerema11, Susheela Tridandapani12, Michael A Freitas13, Natarajan Muthusamy14, John C Byrd15.   

Abstract

Tetraspanins are commonly believed to act only as "molecular facilitators," with no direct role in signal transduction. We herein demonstrate that upon ligation, CD37, a tetraspanin molecule expressed on mature normal and transformed B cells, becomes tyrosine phosphorylated, associates with proximal signaling molecules, and initiates a cascade of events leading to apoptosis. Moreover, we have identified two tyrosine residues with opposing regulatory functions: one lies in the N-terminal domain of CD37 in a predicted "ITIM-like" motif and mediates SHP1-dependent death, whereas the second lies in a predicted "ITAM motif" in the C-terminal domain of CD37 and counteracts death signals by mediating phosphatidylinositol 3-kinase-dependent survival.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22624718      PMCID: PMC3360882          DOI: 10.1016/j.ccr.2012.03.040

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  37 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Signal transduction by human-restricted Fc gamma RIIa involves three distinct cytoplasmic kinase families leading to phagocytosis.

Authors:  D S Cooney; H Phee; A Jacob; K M Coggeshall
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

3.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

4.  Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor.

Authors:  M Loeffler; E Daugas; S A Susin; N Zamzami; D Metivier; A L Nieminen; G Brothers; J M Penninger; G Kroemer
Journal:  FASEB J       Date:  2001-03       Impact factor: 5.191

5.  Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Authors:  Lapo Alinari; Bo Yu; Beth A Christian; Fengting Yan; Jungook Shin; Rosa Lapalombella; Erin Hertlein; Mark E Lustberg; Carl Quinion; Xiaoli Zhang; Gerard Lozanski; Natarajan Muthusamy; Mette Prætorius-Ibba; Owen A O'Connor; David M Goldenberg; John C Byrd; Kristie A Blum; Robert A Baiocchi
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

6.  A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

Authors:  Karl-Heinz Heider; Kerstin Kiefer; Thorsten Zenz; Matthias Volden; Stephan Stilgenbauer; Elinborg Ostermann; Anke Baum; Herbert Lamche; Zaruhi Küpcü; Alexander Jacobi; Steffen Müller; Ulrich Hirt; Günther R Adolf; Eric Borges
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

7.  Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions.

Authors:  K P Knobeloch; M D Wright; A F Ochsenbein; O Liesenfeld; J Löhler; R M Zinkernagel; I Horak; Z Orinska
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.

Authors:  Rosa Lapalombella; Bo Yu; Georgia Triantafillou; Qing Liu; Jonathan P Butchar; Gerard Lozanski; Asha Ramanunni; Lisa L Smith; William Blum; Leslie Andritsos; Da-Sheng Wang; Amy Lehman; Ching-Shih Chen; Amy J Johnson; Guido Marcucci; Robert J Lee; L James Lee; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2008-09-04       Impact factor: 22.113

View more
  52 in total

1.  Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Authors:  Zachary A Hing; Rose Mantel; Kyle A Beckwith; Daphne Guinn; Erich Williams; Lisa L Smith; Katie Williams; Amy J Johnson; Amy M Lehman; John C Byrd; Jennifer A Woyach; Rosa Lapalombella
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.

Authors:  Daniel S Pereira; Claudia I Guevara; Liqing Jin; Nathan Mbong; Alla Verlinsky; Ssucheng J Hsu; Hector Aviña; Sher Karki; Joseph D Abad; Peng Yang; Sung-Ju Moon; Faisal Malik; Michael Y Choi; Zili An; Kendall Morrison; Pia M Challita-Eid; Fernando Doñate; Ingrid B J Joseph; Thomas J Kipps; John E Dick; David R Stover
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

Review 3.  Targeted therapies in CLL: mechanisms of resistance and strategies for management.

Authors:  Jennifer A Woyach; Amy J Johnson
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 4.  The biology behind PI3K inhibition in chronic lymphocytic leukaemia.

Authors:  Valentín Ortiz-Maldonado; Marcial García-Morillo; Julio Delgado
Journal:  Ther Adv Hematol       Date:  2015-02

5.  SMIP-016 in action: CD37 as a death receptor.

Authors:  Lei Jin; John C Cambier
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

Review 6.  Tetraspanin proteins promote multiple cancer stages.

Authors:  Martin E Hemler
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

7.  Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Authors:  Jason A Dubovsky; Ryan Flynn; Jing Du; Bonnie K Harrington; Yiming Zhong; Benjamin Kaffenberger; Carrie Yang; William H Towns; Amy Lehman; Amy J Johnson; Natarajan Muthusamy; Steven M Devine; Samantha Jaglowski; Jonathan S Serody; William J Murphy; David H Munn; Leo Luznik; Geoffrey R Hill; Henry K Wong; Kelli K P MacDonald; Ivan Maillard; John Koreth; Laurence Elias; Corey Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Angela Panoskaltsis-Mortari; John C Byrd; Bruce R Blazar
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

8.  IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.

Authors:  Shuai Dong; Daphne Guinn; Jason A Dubovsky; Yiming Zhong; Amy Lehman; Jeffery Kutok; Jennifer A Woyach; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2014-09-25       Impact factor: 22.113

9.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Authors:  Ajay K Gopal; Stefano R Tarantolo; Naresh Bellam; Damian J Green; Melissa Griffin; Tatyana Feldman; Anthony R Mato; Amy J Eisenfeld; Scott C Stromatt; Andre Goy
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

10.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.